{"preliminary_commentary":{"by_channel":{"x_thread":6},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"name":"IMPACT2","nct_id":"NCT02152254","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=impact2-nct02152254. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Personalized treatment, targeted therapy against the alteration based on molecular profiling.","label":"Arm A: Targeted Therapy","type":"ACTIVE_COMPARATOR"},{"description":"Standard-of-Care treatment not selected on basis of alteration analysis.","label":"Arm B: Standard-of-Care Therapy","type":"EXPERIMENTAL"}],"collaborators":["Tempus AI"],"completion_date":{"date":"2030-12-31","type":"ESTIMATED"},"conditions":["Metastatic Malignant Neoplasm","Recurrent Malignant Neoplasm"],"enrollment":{"count":1362,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Targeted Therapy Based on Molecular Profiling","otherNames":[],"type":"DRUG"},{"name":"Standard-of-Care Therapy","otherNames":[],"type":"DRUG"}],"last_update":"2026-08-10","lead_sponsor":"M.D. Anderson Cancer Center","official_title":"Randomized Study Evaluating Molecular Profiling and Targeted Agents in Metastatic Cancer: Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT II)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2030-12-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Comparison of Progression-Free Survival (PFS) Between the Two Randomized Arms","timeFrame":"Continuous Monitoring, expected range from 2 months to 3 years"}],"references":[{"citation":"Vo HH, Fu S, Hong DS, Karp DD, Piha-Paul S, Subbiah V, Janku F, Naing A, Yap TA, Rodon J, Ajani JA, Cartwright C, Johnson A, Song IW, Beck J, Kahle M, Nogueras-Gonzalez GM, Miller V, Chao C, Vining DJ, Berry DA, Meric-Bernstam F, Tsimberidou AM. Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology. NPJ Precis Oncol. 2022 Oct 27;6(1):78. doi: 10.1038/s41698-022-00317-0.","pmid":"36302890","type":"DERIVED"},{"citation":"Naqvi MF, Vo HH, Vining D, Tsimberidou AM. Prolonged response to treatment based on cell-free DNA analysis and molecular profiling in three patients with metastatic cancer: a case series. Ther Adv Med Oncol. 2021 Mar 24;13:17588359211001538. doi: 10.1177/17588359211001538. eCollection 2021.","pmid":"33995588","type":"DERIVED"},{"citation":"Aletaha D, Alasti F, Smolen JS. Disease activity states of the DAPSA, a psoriatic arthritis specific instrument, are valid against functional status and structural progression. Ann Rheum Dis. 2017 Feb;76(2):418-421. doi: 10.1136/annrheumdis-2016-209511. Epub 2016 Jul 25.","pmid":"27457512","type":"DERIVED"}],"start_date":{"date":"2014-05-13","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT II)","url":"https://clinicaltrials.gov/study/NCT02152254"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/impact2-nct02152254"}